THE UNITED LABORATORIES INTERNATIONAL HOLDINGS LIMITED

The United Laboratories International Holdings Limited

3933

KYG8813K1085

Pharmaceuticals

Market Closed - Hong Kong S.E. Other stock markets 04:08:07 2024-07-05 EDT			5-day change	1st Jan Change
8.24 ^HKD	-0.60%		0.00%	+17.55%

06-20	The United Laboratories International Holdings Limited Declares Final Dividend for the Year Ended 31 December 2023, Payable on 24 July 2024	CI
06-20	The United Laboratories International Holdings Limited Declares Special Dividend for the Year Ended 31 December 2023, Payable on 24 July 2024	CI

The United Laboratories International Holdings Limited Declares Special Dividend for the Year Ended 31 December 2023, Payable on 24 July 2024

June 20, 2024 at 07:53 am

The United Laboratories International Holdings Limited announced at the AGM held on June 20, 2024, approved a special dividend of RMB 0.12 per share for the year ended 31 December 2023. Ex-dividend date is 02 July 2024, Record date is 05 July 2024 and Payment date is 24 July 2024.

Latest news about The United Laboratories International Holdings Limited

The United Laboratories International Holdings Limited Declares Final Dividend for the Year Ended 31 December 2023, Payable on 24 July 2024	06-20	CI
The United Laboratories International Holdings Limited Declares Special Dividend for the Year Ended 31 December 2023, Payable on 24 July 2024	06-20	CI
Chinese drugmakers developing generic drugs of Novo Nordisk's Ozempic	06-05	RE
Novo Nordisk braces for generic challenge to Ozempic, Wegovy in China	06-05	RE
United Laboratories Proposes Final, Special Dividend for 2023	05-08	MT
The United Laboratories International Holdings Limited Reports Earnings Results for the Full Year Ended December 31, 2023	03-26	CI
The United Laboratories International's 2023 Profit Rises on Higher Revenue	03-26	MT
The United Laboratories International Holdings Limited Recommends Payment of Final Dividend for the Year Ended 31 December 2023	03-26	CI
The United Laboratories International Holdings Limited Recommends Payment of Special Dividend for the Year Ended 31 December 2023	03-26	CI
The United Laboratories International Forecasts Profit Surge in 2023	03-14	MT
The United Laboratories International Holdings Limited Provides Consolidated Earnings Guidance for the Year Ended 31 December 2023	03-14	CI
United Laboratories Postpones EGM Due to Bad Weather	23-10-09	MT
United Laboratories Subsidiary Gets US FDA Nod for Injectable for Diabetes; Shares Rise 8%	23-09-26	MT
The United Laboratories International Holdings Limited Announces FDA Approval of IND for UBT251 Injection	23-09-26	CI
The United Laboratories International Holdings Limited Announces Interim Dividend for Six Months Ended 30 June 2023, Payable on 11 October 2023	23-09-21	CI
United Laboratories Controlling Shareholder to Sell 64 Million Shares	23-09-19	MT
United Laboratories International Unit Gets Regulatory Nod to Conduct Trial on TUL01101 Tablets	23-09-11	MT
Chinese Regulator Allows Clinical Trial of United Laboratories' Fatty-Liver Drug	23-09-08	MT
The United Laboratories International Holdings Limited Announces Application for the Clinical Trial of Class 1 Innovative New Drug UBT251 Injection	23-09-08	CI
United Laboratories International Says Two Products Pass Consistency Evaluation	23-09-07	MT
China Greenlights United Laboratories' Clinical Trial for Obesity Injection; Shares Rise 4%	23-09-03	MT
The United Laboratories International Holdings Limited Announces Approval for Clinical Trial of Ubt251 Injection on Indication of Overweight or Obesity	23-09-03	CI
The United Laboratories International Holdings Limited Announces Ordinary Interim (Semi-Annual) Dividend for Six Months Ended 30 June 2023	23-08-30	CI
United Laboratories' H1 Profit Doubles; Shares Fall 4%	23-08-30	MT
The United Laboratories International Holdings Limited Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-29	CI

Chart The United Laboratories International Holdings Limited

Duration

Period

Chart The United Laboratories International Holdings Limited

More charts

Company Profile

The United Laboratories International Holdings Limited is an investment holding company principally engaged in the sales of intermediate products, bulk medicine and finished products. The Company operates its business through three segments. The Intermediate Products segment is engaged in the sale of intermediate products. The Bulk Medicine segment is engaged in the sale of bulk medicine. The Finished Products segment is engaged in the sale of antibiotics finished products, non-antibiotics finished products and capsule casings. Through its subsidiaries, the Company is also engaged in the production and sale of organic fertilizer.

Sector

Pharmaceuticals

Calendar

2024-08-26 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for The United Laboratories International Holdings Limited

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

8.24 HKD

Average target price

12.28 HKD

Spread / Average Target

+49.08%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
THE UNITED LABORATORIES INTERNATIONAL HOLDINGS LIMITED	+17.55%	1.92B
ELI LILLY AND COMPANY	+56.89%	823B
NOVO NORDISK A/S	+39.52%	627B
JOHNSON & JOHNSON	-6.55%	353B
MERCK & CO., INC.	+15.99%	320B
ABBVIE INC.	+7.92%	295B
ASTRAZENECA PLC	+13.74%	239B
NOVARTIS AG	+13.83%	220B
ROCHE HOLDING AG	-0.49%	219B
AMGEN INC.	+7.94%	167B

Other Pharmaceuticals